Analysis-Obesity battle heats up again as Novo claws way back into race with Lilly

By Maggie Fick and Bhanvi Satija LONDON, Aug 3 – Novo Nordisk investors have found little cause for optimism during a bruising two-year period of profit warnings, leadership upheaval and a sliding

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)